Getz, Gad
Mayo Clinic
Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Citations 2
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Ghobrial, Irene M. , Kumar, Shaji , Mateos, María‐Victoria , Bergsagel, P. Leif , Chesi, Marta , Dhodapkar, Madhav V. , Getz, Gad , Manier, Salomon , Nuvolone, Mario , O’Donnell, Elizabeth , Sklavenitis‐Pistofidis, Romanos , Sperling, Adam S. , Vassiliou, George S. , Munshi, Nikhil C. , Bergsagel, P. Leif , Gormley, Nicole , Kumar, Shaji K , Mateos, María-Victoria , Chesi, Marta , Dhodapkar, Madhav V , Getz, Gad , Kastritis, Efstathios , Kristinsson, Sigurdur Y , Martinez-Climent, Jose Angel , Manier, Salomon , Marinac, Catherine R , Maura, Francesco , Morgan, Gareth J , Davies, Faith E , Nadeem, Omar , Nuvolone, Mario , Paiva, Bruno , O'Donnell, Elizabeth , Prosper, Felipe , Shah, Urvi A , Sklavenitis-Pistofidis, Romanos , Sperling, Adam S , Munshi, Nikhil C , Castle, Philip E , Anderson, Kenneth C , San-Miguel, Jesus , Ghobrial, Irene M , Gormley, Nicole , Dispenzieri, Angela , Fonseca, Rafaël , Kastritis, Efstathios , Martinez‐Climent, José A. , Marinac, Catherine R. , Maura, Francesco , Morgan, Gareth J. , Davies, Faith E. , Nadeem, Omar , Paiva, Bruno , Prósper, Felipe , Shah, Urvi A. , Anderson, Kenneth C. , Miguel, Jesús F. San
Blood Cancer Discovery | March 5, 2024 | Volume: 5 | Issue: 3 | Pages: 146-152
Summary: While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment.
MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology
Dutta, Ankit K. , Alberge, Jean-Baptiste , Lightbody, Elizabeth D. , Boehner, Cody J. , Dunford, Andrew , Sklavenitis‐Pistofidis, Romanos , Mouhieddine, Tarek H. , Cowan, Annie , Su, Nang Kham , Horowitz, Erica , Barr, Hadley , Hevenor, Laura , Perry, Jacqueline , Cao, Amanda , Lin, Ziao , Kuhr, Frank K. , Mastro, Richard G. Del , Greipp, Patricia T. , Auclair, Daniel , Ghobrial, Irene M. , Cowan, Annie N , Horowitz, Erica M , Beckwith, Jenna B , Perry, Jacqueline , Cao, Amanda , Lin, Ziao , Kuhr, Frank K , Mastro, Richard G Del , Nadeem, Omar , Greipp, Patricia T , Stewart, Chip , Auclair, Daniel , Getz, Gad , Ghobrial, Irene M , Sklavenitis-Pistofidis, Romanos , Su, Nang K , Alberge, Jean-Baptiste , Nadeem, Omar , Getz, Gad
Cancer Discovery | December 7, 2022 | Volume: 13 | Issue: 2 | Pages: 348-363
Abstract Multiple myeloma (MM) develops from well-defined precursor stages; however, invasive bone marrow (BM) biopsy limits screening and monitoring strategies for patients. We enumerated circulating tumor cells (CTC) from 261 patients (84 monoclonal gammopathy of undetermined significance, 155 smoldering multiple myeloma, and 22 MM), with neoplastic cells detected in 84%. We developed a novel approach, MinimuMM-seq, which enables the detection of translocations and copy-number abnormalities through whole-genome sequencing of highly pure CTCs. Application to CTCs in a cohort of 51 patients, 24 with paired BM, was able to detect 100% of clinically reported BM biopsy events and could replace molecular cytogenetics for diagnostic yield and risk classification. Longitudinal sampling of CTCs in 8 patients revealed major clones could be tracked in the blood, with clonal evolution and shifting dynamics of subclones over time. Our findings provide proof of concept that CTC detection and genomic profiling could be used clinically for monitoring and managing disease in MM. Significance: In this study, we established an approach enabling the enumeration and sequencing of CTCs to replace standard molecular cytogenetics. CTCs harbored the same pathognomonic MM abnormalities as BM plasma cells. Longitudinal sampling of serial CTCs was able to track clonal dynamics over time and detect the emergence of high-risk genetic subclones. This article is highlighted in the In This Issue feature, p. 247